Welcome to our dedicated page for NewAmsterdam Pha SEC filings (Ticker: namsw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pha's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pha's regulatory disclosures and financial reporting.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.
NewAmsterdam Pharma Company N.V. furnished an updated investor presentation that highlights the development and commercialization plans for its CETP inhibitor obicetrapib.
The company describes obicetrapib as a once-daily oral therapy that produced LDL-C reductions of about 35–40% as monotherapy and roughly 50–60% when combined with ezetimibe across multiple Phase 2 and Phase 3 trials, with additional ~45% Lp(a) lowering versus placebo in pooled analyses. Exploratory analyses from the Phase 3 BROADWAY trial showed an observed 21% reduction in major adverse cardiovascular events at one year versus placebo, with pooled BROADWAY and BROOKLYN data also favoring obicetrapib, while noting these studies were not powered for outcomes.
The presentation outlines a potential global peak sales opportunity of more than $8 billion for cardiometabolic use, citing over 30 million U.S. patients on lipid-lowering drugs who are not at LDL-C goal. It also reports cash, cash equivalents and marketable securities of approximately $729 million at year-end 2025, intended to support a prospective U.S. launch if approved. Additional data show a 2.84% treatment benefit on p‑tau217 progression overall and a 20.5% benefit in ApoE4 homozygotes over 12 months, along with favorable changes in other Alzheimer’s biomarkers. The company emphasizes intellectual property protection, including composition-of-matter coverage extending into 2043, and a broad late-stage clinical program, including the PREVAIL cardiovascular outcomes trial and multiple Phase 3 and Phase 2 studies.
NewAmsterdam Pharma Company N.V. furnished an updated investor presentation that highlights the development and commercialization plans for its CETP inhibitor obicetrapib.
The company describes obicetrapib as a once-daily oral therapy that produced LDL-C reductions of about 35–40% as monotherapy and roughly 50–60% when combined with ezetimibe across multiple Phase 2 and Phase 3 trials, with additional ~45% Lp(a) lowering versus placebo in pooled analyses. Exploratory analyses from the Phase 3 BROADWAY trial showed an observed 21% reduction in major adverse cardiovascular events at one year versus placebo, with pooled BROADWAY and BROOKLYN data also favoring obicetrapib, while noting these studies were not powered for outcomes.
The presentation outlines a potential global peak sales opportunity of more than $8 billion for cardiometabolic use, citing over 30 million U.S. patients on lipid-lowering drugs who are not at LDL-C goal. It also reports cash, cash equivalents and marketable securities of approximately $729 million at year-end 2025, intended to support a prospective U.S. launch if approved. Additional data show a 2.84% treatment benefit on p‑tau217 progression overall and a 20.5% benefit in ApoE4 homozygotes over 12 months, along with favorable changes in other Alzheimer’s biomarkers. The company emphasizes intellectual property protection, including composition-of-matter coverage extending into 2043, and a broad late-stage clinical program, including the PREVAIL cardiovascular outcomes trial and multiple Phase 3 and Phase 2 studies.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein reported open-market sales of company ordinary shares. On February 20, 2026, he sold 14,692 shares at a weighted average price of $35.00 per share and 30,789 shares at a weighted average price of $35.46 per share. The filing notes that these sales occurred through multiple trades, with prices ranging from $34.24 to $35.23 for the first block and from $35.24 to $35.86 for the second block. Following these transactions, he directly owned 53,500 ordinary shares of NewAmsterdam Pharma.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein reported open-market sales of company ordinary shares. On February 20, 2026, he sold 14,692 shares at a weighted average price of $35.00 per share and 30,789 shares at a weighted average price of $35.46 per share. The filing notes that these sales occurred through multiple trades, with prices ranging from $34.24 to $35.23 for the first block and from $35.24 to $35.86 for the second block. Following these transactions, he directly owned 53,500 ordinary shares of NewAmsterdam Pharma.
NewAmsterdam Pharma Company N.V. reported a Rule 144 notice for a sale of 6,000 ordinary shares. The sale was reported by Johannes Jacob Pieter Kastelein with a transaction date of 01/05/2026 and proceeds shown as $199,500.
NewAmsterdam Pharma Company N.V. reported a Rule 144 notice for a sale of 6,000 ordinary shares. The sale was reported by Johannes Jacob Pieter Kastelein with a transaction date of 01/05/2026 and proceeds shown as $199,500.
NewAmsterdam Pharma Company N.V. files its annual report describing a late-stage biopharma business built around obicetrapib, an oral CETP inhibitor aimed at lowering LDL cholesterol in high‑risk cardiovascular patients who are not at goal on statins.
Multiple Phase 3 trials (BROADWAY, BROOKLYN and TANDEM) met primary and secondary endpoints with statistically significant LDL-C reductions and safety broadly comparable to placebo. A large cardiovascular outcomes trial, PREVAIL, is underway to evaluate major adverse cardiovascular event benefit.
The company has partnered with Menarini in most of Europe, receiving a €115 million upfront payment, committed €27.5 million R&D funding and potential milestones up to €863 million, plus tiered royalties. EMA, UK and Swiss regulators are reviewing marketing applications, with decisions anticipated in the second half of 2026. A broad patent estate could protect obicetrapib and combinations into the 2040s, and early work is exploring its use in Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. files its annual report describing a late-stage biopharma business built around obicetrapib, an oral CETP inhibitor aimed at lowering LDL cholesterol in high‑risk cardiovascular patients who are not at goal on statins.
Multiple Phase 3 trials (BROADWAY, BROOKLYN and TANDEM) met primary and secondary endpoints with statistically significant LDL-C reductions and safety broadly comparable to placebo. A large cardiovascular outcomes trial, PREVAIL, is underway to evaluate major adverse cardiovascular event benefit.
The company has partnered with Menarini in most of Europe, receiving a €115 million upfront payment, committed €27.5 million R&D funding and potential milestones up to €863 million, plus tiered royalties. EMA, UK and Swiss regulators are reviewing marketing applications, with decisions anticipated in the second half of 2026. A broad patent estate could protect obicetrapib and combinations into the 2040s, and early work is exploring its use in Alzheimer’s disease.